TiGenix NV (NYSE Euronext Brussels: TIG) is a leading European cell therapy company with a marketed product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
For more information please visit

PharmaCell Cell Manufacturing Facility (CMF) B.V.
Visit Address:
Urmonderbaan 20B
(Chemelot Gate 2)
6167 RD  Geleen
Postal Address:
P.O. Box 1331
6201 BH  Maastricht
The Netherlands
T. +31 (0)43 350 9910